Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRIUMVI vs BLENREP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BRIUMVI (ublituximab) is a recombinant, chimeric, humanized monoclonal antibody that binds to CD20, a transmembrane antigen expressed on pre-B and mature B lymphocytes. Binding to CD20 results in antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to B-cell depletion.
Belantamab mafodotin is an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) on multiple myeloma cells. The monoclonal antibody component binds to BCMA, leading to internalization and release of the cytotoxic agent monomethyl auristatin F (MMAF), which disrupts microtubule polymerization and induces apoptosis.
Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
FDA-approved for relapsed or refractory multiple myeloma in adults who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent
BRIUMVI (ublituximab) 150 mg administered as an intravenous infusion over 4 hours once weekly for 3 weeks, then 150 mg once every 6 months thereafter.
2.5 mg/kg (actual body weight) intravenously over 30 minutes on day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
Terminal elimination half-life is approximately 19-20 days (range 11-30 days) in patients with relapsing multiple sclerosis. The long half-life supports every-6-month dosing.
The terminal elimination half-life of belantamab mafodotin is approximately 12 days (range 9-19 days). This supports a dosing interval of every 3 weeks, allowing for drug clearance between cycles while maintaining therapeutic exposure.
Ublituximab is a monoclonal antibody catabolized into small peptides and amino acids via general protein degradation pathways; no specific metabolic enzymes are involved.
Belantamab mafodotin is likely metabolized via proteolytic degradation into small peptides and amino acids; MMAF is a substrate of CYP3A and P-glycoprotein, but the contribution of CYP3A to clearance is limited.
BRIUMVI (ublituximab) is a monoclonal antibody. Elimination occurs via intracellular catabolism and is not excreted renally or fecally in significant amounts. No specific excretion data available.
Blenrep (belantamab mafodotin) is eliminated primarily via catabolism, with no significant renal or biliary excretion of intact drug. The small molecule toxin, monomethyl auristatin F (MMAF), is excreted via feces (72%) and urine (28%) after release from the antibody conjugate.
Not extensively bound to plasma proteins (expected low binding for monoclonal antibodies); specific % not reported.
Belantamab mafodotin is highly protein-bound (>99%) to plasma proteins, predominantly to albumin. The released MMAF is also extensively protein-bound (approximately 90% to albumin).
Approximately 3.5 L (not weight-based; ~0.05 L/kg for a 70 kg patient). Small Vd consistent with limited extravascular distribution of monoclonal antibodies.
The volume of distribution of belantamab mafodotin is approximately 7.8 L (range 4.5-12.4 L), which is slightly greater than plasma volume, indicating limited extravascular distribution. The Vd is not typically normalized to body weight; however, dosing is weight-based (mg/kg) to account for interpatient variability.
100% (intravenous administration only; not administered via other routes).
Blenrep is administered as an intravenous infusion; thus, bioavailability is 100% by the intravenous route. No oral or other routes are approved.
No dose adjustment is recommended for patients with mild to moderate renal impairment. Not studied in severe renal impairment (GFR <30 m L/min) or end-stage renal disease.
For moderate renal impairment (e GFR 30-59 m L/min/1.73 m²): reduce dose to 1.9 mg/kg. For severe renal impairment (e GFR 15-29 m L/min/1.73 m²): not recommended. For e GFR <15 m L/min/1.73 m²: contraindicated.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose to 1.9 mg/kg. Child-Pugh Class C: not recommended.
Safety and effectiveness in pediatric patients (age <18 years) have not been established. No recommended dosing.
Safety and efficacy not established; no specific pediatric dosing guidelines available.
No specific dose adjustment is recommended. Clinical studies did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.
No specific dose adjustment recommended based on age alone; monitor renal function and consider dose adjustment per renal impairment guidelines.
None
WARNING: OCULAR TOXICITY. Blenrep (belantamab mafodotin) causes severe ocular toxicity, including keratopathy and changes in visual acuity, which may require dose modification or discontinuation. Perform ophthalmic exams prior to each dose. Use only in patients who have received at least 4 prior therapies.
Infusion reactions (may require premedication and monitoring),Increased risk of infections (including serious and life-threatening infections),Progressive multifocal leukoencephalopathy (PML) in patients treated with anti-CD20 therapies,Hepatitis B reactivation (perform HBV screening before initiation),Immunoglobulin levels reduction requiring monitoring,Increased risk of malignancies (breast cancer observed in clinical trials)
Ocular toxicity (keratopathy, visual acuity changes),Thrombocytopenia,Infusion-related reactions,Hepatotoxicity (increased transaminases),Embryo-fetal toxicity
Active hepatitis B infection,Severe, active infections (until resolved)
None known
No known food interactions. Grapefruit and other CYP450 modulators are not expected to affect ublituximab as it is a monoclonal antibody cleared via catabolism.
No specific food interactions known. Maintain adequate hydration.
BRIUMVI (ublituximab) is a monoclonal antibody, and Ig G antibodies are known to cross the placenta increasingly after the first trimester, with highest transfer in the third trimester. Based on its mechanism of action (CD20-mediated B-cell depletion), there is a potential risk of transient peripheral B-cell depletion in the fetus. Animal studies have not been conducted with ublituximab; however, other anti-CD20 antibodies have shown no teratogenicity but can cause neonatal B-cell depletion. The drug should be avoided during pregnancy unless the benefit justifies the potential risk.
FDA Pregnancy Category D. First trimester: belantamab mafodotin is an antibody-drug conjugate; the cytotoxic component may cause fetal harm. Second and third trimesters: risk of fetal toxicity and teratogenicity due to the microtubule inhibitor; avoid use unless maternal benefit outweighs risk.
It is unknown whether ublituximab is excreted in human milk. Monoclonal antibodies are generally present in breast milk in low amounts, but absorption by the infant is limited due to gastrointestinal degradation. Since ublituximab can cause B-cell depletion, a risk to the breastfed infant cannot be excluded. The M/P ratio is not known.
No data on presence in human milk. M/P ratio unknown. Advise to discontinue breastfeeding during treatment and for at least 3 months after last dose due to potential for severe adverse reactions in breastfed infants.
No specific dose adjustments are recommended during pregnancy due to lack of pharmacokinetic data. However, pregnancy can alter clearance and volume of distribution for monoclonal antibodies, potentially affecting exposure. Current guidelines do not specify dose modifications for ublituximab in pregnancy; clinical judgment is advised.
No specific dose adjustments in pregnancy established. Use is not recommended; if unavoidable, consider dose reduction based on tolerability (e.g., for ocular toxicity). No pharmacokinetic data available to guide adjustments.
Premedicate with corticosteroids, antihistamines, and acetaminophen to reduce infusion reactions. Monitor for hypersensitivity reactions, especially during first infusion. Screen for hepatitis B and tuberculosis before initiation. Avoid live vaccines during treatment. Consider JCV antibody status due to risk of progressive multifocal leukoencephalopathy (PML) with anti-CD20 therapies.
Monitor for ocular toxicity, including keratitis and uveitis; perform ophthalmic exams at baseline and during therapy. Premedicate with corticosteroids and vasoconstrictors to reduce infusion reactions. Blenrep is a BCMA-directed antibody-drug conjugate for relapsed/refractory multiple myeloma. Avoid in patients with severe renal impairment (Cr Cl <30 m L/min).
You must take premedications before each infusion to lower the risk of allergic reactions.,Report any symptoms like fever, chills, rash, or difficulty breathing during or after infusion.,Inform your doctor if you have a history of hepatitis B, tuberculosis, or any infections.,Do not receive live vaccines while on this medication and for a period after stopping.,This drug may increase your risk of infections; contact your doctor if you develop signs of infection.,You will need regular blood tests to monitor for side effects.
Inform your doctor immediately if you experience blurred vision, eye pain, or light sensitivity.,You will need eye exams before and during treatment.,Report any signs of infusion reactions such as chills, fever, or difficulty breathing.,Use effective contraception during treatment and for 4 months after the last dose.,Avoid driving or operating machinery if you have vision changes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRIUMVI vs BLENREP, answered by our medical review team.
BRIUMVI is a Monoclonal Antibody that works by BRIUMVI (ublituximab) is a recombinant, chimeric, humanized monoclonal antibody that binds to CD20, a transmembrane antigen expressed on pre-B and mature B lymphocytes. Binding to CD20 results in antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to B-cell depletion.. BLENREP is a Antineoplastic, Monoclonal Antibody that works by Belantamab mafodotin is an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) on multiple myeloma cells. The monoclonal antibody component binds to BCMA, leading to internalization and release of the cytotoxic agent monomethyl auristatin F (MMAF), which disrupts microtubule polymerization and induces apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRIUMVI and BLENREP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRIUMVI is: BRIUMVI (ublituximab) 150 mg administered as an intravenous infusion over 4 hours once weekly for 3 weeks, then 150 mg once every 6 months thereafter.. The standard adult dose of BLENREP is: 2.5 mg/kg (actual body weight) intravenously over 30 minutes on day 1 of each 21-day cycle until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRIUMVI and BLENREP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRIUMVI is classified as Category C. BRIUMVI (ublituximab) is a monoclonal antibody, and IgG antibodies are known to cross the placenta increasingly after the first trimester, with highest transfer in the third trimes. BLENREP is classified as Category C. FDA Pregnancy Category D. First trimester: belantamab mafodotin is an antibody-drug conjugate; the cytotoxic component may cause fetal harm. Second and third trimesters: risk of fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.